Anal Cancer Clinical Trials 2023

What are the top hospitals conducting anal cancer research?

When it comes to advancing the treatment options for anal cancer, a number of top hospitals are making significant strides. In Kingman, Arizona, the Kingman Regional Medical Center is leading the way with three active clinical trials focused on this specific type of cancer. While their track record may be relatively new, having recorded their first trial in 2018, they are already demonstrating a commitment to finding innovative solutions.

On the West Coast, the University of California, San Francisco is also dedicated to tackling anal cancer through research and clinical trials. With three ongoing trials and four completed studies since their inaugural trial in 2008, this esteemed institution is making notable contributions towards improving outcomes for patients.

Meanwhile, at the National Institutes of Health Clinical Center located in Bethesda, Maryland researchers are actively conducting three clinical trials focusing on anal cancer. Having initiated their very first trial in 2018 as well and completing five studies overall thus far; this center showcases its dedication toward understanding and combatting this particular form of cancer.

In Edmonton Canada's Cross Cancer Institute has been diligently working on adding up scientific insight regarding anal cancer through two current investigational methods while having conducted just as many tests since embarking upon them lately back from2018 reflecting an enthusiasm driving progress here too!

Finally joining these institutions Anchorage Associates in Radiation Medicine situated amidst Alaska's breathtaking landscape come forward with equal vigor contributing by running two currently running experiments dealing with such delicate cases concerning our topic; however like other testing facilities mentioned earlier theirs can be traced back only till recent years namely2018 but nevertheless holds great potential expanding avenues facilitating improvisation when it comes down fighting against diseases like these .

These hospitals demonstrate that even though resources might vary or some efforts relatively newer compared to others.The collective pursuit towards conquering anal cancers remains unyielding across geographical boundaries.Throughout these locations we see how healthcare professionals around world continue striving relentlessly bringing us closer each day,to better treatments which promise brighter futures for patients affected by anal cancer.

Which are the best cities for anal cancer clinical trials?

When it comes to anal cancer clinical trials, several cities in the United States are at the forefront of research. Los Angeles, California leads with 16 active trials studying treatments like Nivolumab and pembrolizumab. Anchorage, Alaska follows closely behind with 15 ongoing studies focusing on interventions such as Nivolumab and Intensity-Modulated Radiation Therapy. Additionally, Houston, Texas has 10 active trials investigating factors like prior HPV for Anal Neoplasia and pembrolizumab. These cities offer individuals battling anal cancer access to cutting-edge clinical trials that contribute to advancements in care and improve outcomes.

Which are the top treatments for anal cancer being explored in clinical trials?

Exciting advancements are being made in the realm of anal cancer treatment, with several potential breakthroughs currently being explored in clinical trials. Leading the pack is nivolumab, a drug that is undergoing testing in four active trials specifically focused on anal cancer. Since its initial listing in 2015, it has been involved in a total of four clinical trials for this disease. Also showing promise is M7824, which is being investigated through two ongoing trials and has been featured in three previous anal cancer studies since its introduction in 2018. In addition to these targeted treatments, research also indicates the potential benefits of discontinuing PD-1/PD-L1 inhibitors and utilizing the 9-valent HPV vaccination as strategies for managing anal cancer progression. As these innovative approaches continue to undergo rigorous examination, they hold great hope for improving outcomes and quality of life for those affected by anal cancer.

What are the most recent clinical trials for anal cancer?

Exciting developments in the realm of anal cancer research offer new hope and potential treatment options for patients. Amongst the most recent clinical trials is a study investigating reduced elective dose combined with concurrent capecitabine/mitomycin C, which aims to improve outcomes for individuals battling this type of cancer. Additionally, another trial focuses on chemo-radiation treatment as a potential approach to managing anal cancer. Promising results have also been observed in a phase 2 trial exploring E7 TCR-T cells as an innovative therapy for this condition. Furthermore, single-agent KFA115 shows promise as a potential treatment option based on early-phase studies. Lastly, ongoing investigation into the effectiveness of 9-valent HPV vaccination provides further avenues for prevention and management strategies related to anal cancer. These groundbreaking trials hold great promise and may lead to significant advancements in treating anal cancer.

What anal cancer clinical trials were recently completed?

Several notable clinical trials focusing on anal cancer have recently been completed, signifying important advancements in the field of treatment. In May 2019, Xencor, Inc. wrapped up a trial investigating XmAb®22841 therapy for this specific type of cancer. Another significant trial was completed in November 2018 by M.D. Anderson Cancer Center, which explored the potential benefits of Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy. Additionally, Xencor conducted a study on XmAb20717 that concluded in July 2018. Finally, the National Cancer Institute's trial examining M7824 reached its completion milestone in February 2018. These successful trials contribute to our understanding and future management approaches for anal cancer patients and highlight ongoing efforts towards improved treatments.